Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 17/20 | 0.65 |
| ▸ | PIK3CA known ✓ | P42336 | 9/20 | 0.65 |
| ▸ | PIK3CD known ✓ | O00329 | 11/20 | 0.62 |
| ▸ | PIK3CG known ✓ | P48736 | 7/20 | 0.62 |
| ▸ | PIK3CB known ✓ | P42338 | 6/20 | 0.62 |
| ▸ | JAK3 known ✓ | P52333 | 3/20 | 0.62 |
| ▸ | PIK3R1 known ✓ | P27986 | 2/20 | 0.62 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 0.62 |
| ▸ | BTK known ✓ | Q06187 | 2/20 | 0.47 |
| ▸ | PIK3C2A | O00443 | 3/20 | 0.65 |
| ▸ | PIK3C2B | O00750 | 3/20 | 0.65 |
| ▸ | PRKDC | P78527 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.62 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.62 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.62 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
| ▸ | MET | P08581 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL994770 | 1.00 | MTOR (0.65) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL993850 | 0.93 | MTOR (0.73) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| Fumaric Acid SCHEMBL994151 | 0.88 | MTOR (0.69) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| Maleic Acid SCHEMBL994149 | 0.88 | MTOR (0.69) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| Maleic Acid SCHEMBL996441 | 0.87 | MTOR (0.55) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| Fumaric Acid SCHEMBL996442 | 0.87 | MTOR (0.55) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL928310 | 0.85 | MTOR (0.67) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL15747835 | 0.85 | MTOR (0.69) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| Maleic Acid SCHEMBL993555 | 0.84 | MTOR (0.54) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| Fumaric Acid SCHEMBL993556 | 0.84 | MTOR (0.54) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2292617-B1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-1888578-B9 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2012-04-25 | — | — | EP | disclosed |
| EP-1888578-B1 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2011-10-13 | — | — | US | disclosed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | PI4KA, PDPK1, PI4KB | MTOR 171/4885PIK3CA 29/4885PIK3CD 58/4885 |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.